First Assessment of the Performance of an Implantable CGM System through 180 Days in a Primarily Adolescent Population with Type 1 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-13-or
Abstract: Background: An implantable continuous glucose monitoring (CGM) system (Eversense ® XL, Senseonics, Maryland U.S.A) recently received CE Mark for 180-day duration in adults. The current study is the first investigation of the performance of the… read more here.
Keywords: primarily adolescent; system; cgm system; adolescent population ... See more keywords